226 related articles for article (PubMed ID: 27236168)
1. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
Mattes JA
J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
[TBL] [Abstract][Full Text] [Related]
2. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
Sallee F; Connor DF; Newcorn JH
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
[TBL] [Abstract][Full Text] [Related]
3. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
Sallee FR
Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
[TBL] [Abstract][Full Text] [Related]
4. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
6. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
Alamo C; López-Muñoz F; Sánchez-García J
Actas Esp Psiquiatr; 2016 May; 44(3):107-12. PubMed ID: 27254403
[TBL] [Abstract][Full Text] [Related]
7. [α2-Adrenergic agonists, and drugs for ADHD].
Clement HW; Schulz E
Pharm Unserer Zeit; 2011 Nov; 40(6):503-9. PubMed ID: 22028136
[No Abstract] [Full Text] [Related]
8. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
Kawaura K; Karasawa J; Chaki S; Hikichi H
Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
[TBL] [Abstract][Full Text] [Related]
10. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
Bukstein OG; Head J
Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
Huang YS; Tsai MH
CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
[TBL] [Abstract][Full Text] [Related]
12. ▼Guanfacine for ADHD in children and adolescents.
Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
[TBL] [Abstract][Full Text] [Related]
13. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
14. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
Mattingly GW; Anderson RH
CNS Spectr; 2016 Dec; 21(S1):45-59. PubMed ID: 28044946
[TBL] [Abstract][Full Text] [Related]
15. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
Scahill L
CNS Drugs; 2009; 23 Suppl 1():43-9. PubMed ID: 19621977
[TBL] [Abstract][Full Text] [Related]
16. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
[TBL] [Abstract][Full Text] [Related]
17. Nonstimulant Treatments for ADHD.
Newcorn JH; Krone B; Dittmann RW
Child Adolesc Psychiatr Clin N Am; 2022 Jul; 31(3):417-435. PubMed ID: 35697393
[TBL] [Abstract][Full Text] [Related]
18. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Kornfield R; Watson S; Higashi AS; Conti RM; Dusetzina SB; Garfield CF; Dorsey ER; Huskamp HA; Alexander GC
Psychiatr Serv; 2013 Apr; 64(4):339-46. PubMed ID: 23318985
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
20. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
